Total Payments
$656,845
2024 Payments
$83,755
Companies
14
Transactions
768
Medicare Patients
2,084
Medicare Billing
$485,161
Payment Breakdown by Category
Other$499,469 (76.0%)
Consulting$87,135 (13.3%)
Travel$49,906 (7.6%)
Food & Beverage$20,322 (3.1%)
Education$11.90 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $496,614 | 190 | 75.6% |
| Consulting Fee | $87,135 | 11 | 13.3% |
| Travel and Lodging | $49,906 | 300 | 7.6% |
| Food and Beverage | $20,322 | 265 | 3.1% |
| Honoraria | $2,855 | 1 | 0.4% |
| Education | $11.90 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $616,088 | 619 | $0 (2024) |
| Lilly USA, LLC | $27,732 | 64 | $0 (2024) |
| Amgen Inc. | $7,144 | 10 | $0 (2019) |
| Orexigen Therapeutics, Inc. | $3,587 | 9 | $0 (2018) |
| Novo Nordisk AS | $1,050 | 1 | $0 (2022) |
| EISAI INC. | $359.71 | 21 | $0 (2019) |
| Intra-Sana Laboratories | $251.01 | 8 | $0 (2024) |
| VIVUS LLC | $244.46 | 13 | $0 (2024) |
| Currax Pharmaceuticals LLC | $203.35 | 13 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $97.55 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $83,755 | 137 | Novo Nordisk Inc ($56,026) |
| 2023 | $45,959 | 67 | Novo Nordisk Inc ($45,721) |
| 2022 | $80,752 | 95 | Novo Nordisk Inc ($79,546) |
| 2021 | $69,557 | 76 | Novo Nordisk Inc ($69,480) |
| 2020 | $70,408 | 70 | Novo Nordisk Inc ($70,356) |
| 2019 | $127,362 | 130 | Novo Nordisk Inc ($119,895) |
| 2018 | $109,823 | 92 | Novo Nordisk Inc ($109,572) |
| 2017 | $69,229 | 101 | Novo Nordisk Inc ($65,490) |
All Payment Transactions
768 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 12/10/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $525.00 | General |
| Category: Obesity | ||||||
| 12/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,437.50 | General |
| Category: Obesity | ||||||
| 12/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $117.76 | General |
| Category: Obesity | ||||||
| 12/02/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Travel and Lodging | Cash or cash equivalent | $15.68 | General |
| Category: Obesity | ||||||
| 11/27/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Travel and Lodging | Cash or cash equivalent | $50.65 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,093.75 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,093.75 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $183.04 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $126.97 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $124.89 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $76.00 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $74.00 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $36.05 | General |
| Category: Obesity | ||||||
| 11/25/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 11/25/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $875.00 | General |
| Category: Obesity | ||||||
| 11/22/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 11/22/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $525.00 | General |
| Category: Obesity | ||||||
| 11/21/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $105.47 | General |
| Category: Obesity | ||||||
| 11/20/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $124.77 | General |
| Category: Obesity | ||||||
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $525.00 | General |
| Category: Obesity | ||||||
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Travel and Lodging | Cash or cash equivalent | $25.06 | General |
| Category: Obesity | ||||||
| 11/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,437.50 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 738 | 2,530 | $384,366 | $164,177 |
| 2022 | 6 | 642 | 2,034 | $334,527 | $141,200 |
| 2021 | 5 | 394 | 1,628 | $243,936 | $110,575 |
| 2020 | 5 | 310 | 1,198 | $178,875 | $69,208 |
Total Patients
2,084
Total Services
7,390
Medicare Billing
$485,161
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 250 | 1,152 | $214,445 | $91,381 | 42.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 171 | 294 | $85,545 | $32,537 | 38.0% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 232 | 999 | $45,055 | $29,680 | 65.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $27,434 | $7,495 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $10,788 | $2,932 | 27.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 11 | 11 | $1,100 | $150.92 | 13.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 180 | 777 | $144,639 | $62,889 | 43.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 154 | 355 | $103,294 | $38,519 | 37.3% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2022 | 180 | 773 | $34,862 | $24,255 | 69.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 71 | 71 | $34,172 | $10,868 | 31.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $13,961 | $4,207 | 30.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 35 | 36 | $3,600 | $462.49 | 12.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 124 | 676 | $125,837 | $56,432 | 44.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 82 | 222 | $64,595 | $26,699 | 41.3% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2021 | 115 | 655 | $29,990 | $21,052 | 70.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 42 | 42 | $20,214 | $5,910 | 29.2% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 31 | 33 | $3,300 | $483.78 | 14.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 97 | 466 | $86,746 | $30,492 | 35.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 200 | $58,194 | $19,482 | 33.5% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2020 | 90 | 481 | $17,397 | $14,623 | 84.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 30 | 30 | $14,439 | $4,280 | 29.6% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 20 | 21 | $2,100 | $331.14 | 15.8% |
About Dr. Michael Kaplan, DO
Dr. Michael Kaplan, DO is a Internal Medicine healthcare provider based in Smithtown, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1841298593.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Kaplan, DO has received a total of $656,845 in payments from pharmaceutical and medical device companies, with $83,755 received in 2024. These payments were reported across 768 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($496,614).
As a Medicare-enrolled provider, Kaplan has provided services to 2,084 Medicare beneficiaries, totaling 7,390 services with total Medicare billing of $485,161. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Smithtown, NY
- Active Since 07/07/2005
- Last Updated 07/26/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1841298593
Products in Payments
- Saxenda (Drug) $428,784
- Wegovy (Drug) $126,965
- ZEPBOUND (Drug) $26,887
- CONTRAVE (Drug) $3,824
- Belviq (Drug) $359.71
- RELTONE 200 MG (Drug) $251.01
- QSYMIA (Drug) $227.46
- TALTZ (Drug) $115.25
- TROKENDI XR (Drug) $97.55
- Ozempic (Drug) $47.85
- VYVANSE (Drug) $24.71
- TRULICITY (Drug) $18.47
- Qsymia (Drug) $17.00
- KRYSTEXXA (Biological) $16.89
- EMGALITY (Drug) $13.45
- SUNOSI (Drug) $12.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Smithtown
Dr. Kristin Macdougall, Md, MD
Internal Medicine — Payments: $14,897
Internal Medicine $14,897
Dr. Anthony Spadaro, M.d, M.D
Internal Medicine — Payments: $13,544
Internal Medicine $13,544
Dr. Richard Gold, Md, MD
Internal Medicine — Payments: $13,513
Internal Medicine $13,513
Deborah Blenner, M.d, M.D
Internal Medicine — Payments: $11,901
Internal Medicine $11,901
Adalbert Pilip, Md, MD
Internal Medicine — Payments: $9,004
Internal Medicine $9,004
Dr. Stephen Littman, M.d, M.D
Internal Medicine — Payments: $6,581
Internal Medicine $6,581